App-Quantinova.ai

Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo

A. El-Khoueiry - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC).

Mark Yarchoan - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Second-line tyrosine kinase inhibitors (TKIs) versus immunotherapy (IO) for advanced hepatocellular carcinoma (HCC): Real-world efficacy and safety analysis in patients with varying liver dysfunction.

Jeffrey Xia - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

A phase I/II trial to evaluate cabozantinib in patients with advanced hepatocellular carcinoma with Child-Pugh class B cirrhosis after first-line therapy.

Thomas Enzler - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Phase II study of cabozantinib (cabo) combined with pembrolizumab (pembro) in metastatic or recurrent gastric and gastroesophageal adenocarcinoma (GEC) to overcome resistance to checkpoint inhibitors.

Farshid Dayyani - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Cabozantinib

The use of cabozantinib in advanced hepatocellular carcinoma (HCC): Hong Kong multi-center experience.

Yawen Dong - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Modeling sequential systemic therapy for unresectable hepatocellular carcinoma in the era of immunotherapy: What comes next?

Ciro Celsa - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC).

Jonathan Thouvenin - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Cabozantinib

Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

Chun Loo Gan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Cabozantinib

Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).

Toni K. Choueiri - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Cabozantinib

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Sumanta K. Pal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Cabozantinib

Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.

Andrea B. Apolo - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Cabozantinib

Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.

Laure Hirsch - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Cabozantinib

Exploring the synergistic effects of cabozantinib (cabo) and a programmed cell death protein 1 (PD1) inhibitor in metastatic renal cell carcinoma (mRCC) with artificial intelligence (AI).

Ignacio Duran - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Cabozantinib

Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with metastatic renal cell carcinoma (mRCC).

Florence Marteau - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Cabozantinib

Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial.

David Cella - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Cabozantinib

Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.

Robert J. Motzer - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Cabozantinib

Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).

Akram Mesleh Shayeb - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Cabozantinib

A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36).

Giuseppe Procopio - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Cabozantinib

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Tian Zhang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Cabozantinib

Filters

366 Abstracts